Abstract
Prostate cancer is a significant public health problem around the world. Once a patient has disease that is no longer addressable by local means, the cancer is considered incurable. Therapeutic goals at this point include not only extension of survival but also alteration of the natural history which may otherwise lead to significant pain and morbidity from the disease process- all related to metastases. While effective systemic therapies do currently exist, their roles are considered limited for many patients. Given the overwhelming incidence and annual mortality figures related to prostate cancer, there continues to be an urgent need for therapeutic advances. Protein kinases have emerged as “druggable” therapeutic targets as they control a multitude of basic cellular activities, including growth, survival, proliferation, differentiation and apoptosis. Several of these kinases have oncogenic properties as in the setting of malignancy they may be overactive and/or dysregulated leading to the excessive proliferation and motility typical of cancer cells. Small molecule inhibitors have shown efficacy in several tumor models and are actively being studied in prostate cancer. This review summarizes historical and contemporary studies evaluating kinase inhibitors in the treatment of prostate cancer.
Anti-Cancer Agents in Medicinal Chemistry
Title: Kinase Inhibitors in Prostate Cancer
Volume: 9 Issue: 10
Author(s): Suwicha Limvorasak and Edwin M. Posadas
Affiliation:
Abstract: Prostate cancer is a significant public health problem around the world. Once a patient has disease that is no longer addressable by local means, the cancer is considered incurable. Therapeutic goals at this point include not only extension of survival but also alteration of the natural history which may otherwise lead to significant pain and morbidity from the disease process- all related to metastases. While effective systemic therapies do currently exist, their roles are considered limited for many patients. Given the overwhelming incidence and annual mortality figures related to prostate cancer, there continues to be an urgent need for therapeutic advances. Protein kinases have emerged as “druggable” therapeutic targets as they control a multitude of basic cellular activities, including growth, survival, proliferation, differentiation and apoptosis. Several of these kinases have oncogenic properties as in the setting of malignancy they may be overactive and/or dysregulated leading to the excessive proliferation and motility typical of cancer cells. Small molecule inhibitors have shown efficacy in several tumor models and are actively being studied in prostate cancer. This review summarizes historical and contemporary studies evaluating kinase inhibitors in the treatment of prostate cancer.
Export Options
About this article
Cite this article as:
Limvorasak Suwicha and Posadas M. Edwin, Kinase Inhibitors in Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789735080
DOI https://dx.doi.org/10.2174/187152009789735080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Herbal Medicine in the Treatment of Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology History and Evolution of Reproductive and Developmental Toxicology Guidelines
Current Pharmaceutical Design Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Carvacrol Exhibits Chemopreventive Potential against Cervical Cancer Cells via Caspase-Dependent Apoptosis and Abrogation of Cell Cycle Progression
Anti-Cancer Agents in Medicinal Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594
Current Pharmaceutical Biotechnology Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ultrasound Therapeutics– A Review
Current Medical Imaging Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Molecules to Selectively Target Receptors for Treatment of Pain and Neurogenic Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism